Table 3 Total savings from patent expiration during 2020–2024 for various scenarios
Scenario | Budget savings | Changes from base case savings | ||||
|---|---|---|---|---|---|---|
Korea (₩): million | US ($): million | % of expendituresa | Korea (₩): million | US ($): million | (%) | |
Base case | ₩234,429 | $203 | 20% | |||
Based on group B cancer drugs | ₩157,633 | $136 | 14% | - ₩76,795 | -$66 | −33% |
Based on group C cancer drugs | ₩434,523 | $376 | 38% | ₩200,095 | $173 | + 85% |
Generic entrance: 6 months delay | ₩165,904 | $144 | 14% | - ₩68,524 | -$59 | −29% |
Risk-sharing scheme rebate of 25% | ₩221,465 | $192 | 19% | -₩12,963 | -$11 | −6% |
Adjustment for reimbursement | ₩210,985 | $183 | 18% | - ₩23,443 | -$20 | −10% |
Growth of off-patent market | ₩255,316 | $221 | 22% | ₩20,888 | $18 | + 9% |
Price level of originators | ₩206,929 | $179 | 18% | -₩27,499 | -$24 | −12% |
Price levels of generics/biosimilars | ₩234,771 | $203 | 20% | ₩343 | $0 | 0% |
New pricing policy (July 2020) | ₩246,082 | $213 | 21% | ₩11,654 | $10 | + 5% |